tbuckley/cabot-search huggingface dataset:
CORONARY ATHEROSCLEROSIS SCORING BY THE LEIDEN CCTA RISK SCORE FOR PREDICTION OF MAJOR ADVERSE CARDIAC EVENTS: A PROPENSITY SCORE-BASED ANALYSIS OF DIABETIC AND NON-DIABETIC PATIENTS
Authors: Inge J. van den Hoogen, Alexander van Rosendael, Fay Lin, Stephan Achenbach, Mouaz H. Al-Mallah, Matthew Budoff, Daniel Berman, Filippo Cademartiri, Hyuk-Jae Chang, Benjamin Chow, Ricardo Cury, Gudrun Feuchtner, Martin Hadamitzky, Joerg Hausleiter, Philipp A. Kaufmann, Jonathon Leipsic, Yong-Jin Kim, Hugo Marques, Gianluca Pontone, Gilbert Raff, Ronen Rubinshtein, Todd Villines, James Min, Jeroen J. Bax
Journal: Journal of the American College of Cardiology (2019)
QUANTITATIVE ASSESSMENT OF ACUTE REGURGITATION FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION: A MULTICENTER POOLED ANALYSIS OF 2,258 VALVES
Authors: Rodrigo G. P Modolo, Chun Chin Chang, Hydeyuki Kawashima, Masafumi Ono, Hiroki Tateishi, Yosuke Miyazaki, Michele Pighi, Mohammad Abdelghani, Joanna Wykrzykowska, Robbert de Winter, Andreas Ruck, Alaide Chieffo, Kyohei Yamaji, Fabio Sandoli Brito, Pedro A. Lemos, Baravan Al-Kassou, Nicolo Piazza, Didier Tchetche, Jan-Malte Sinning, Mohamed Abdel-Wahab, Osama Soliman, Lars Sondergaard, Yoshinobu Onuma, Nicolas Van Mieghem, Patrick Serruys
Journal: Journal of the American College of Cardiology (2020)
Ventilatory Ratio in Hypercapnic Mechanically Ventilated Patients with COVID-19–associated Acute Respiratory Distress Syndrome
Authors: Xiaoqing Liu, Xuesong Liu, Yonghao Xu, Zhiheng Xu, Yongbo Huang, Sibei Chen, Shiyue Li, Dongdong Liu, Zhimin Lin, Yimin Li
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
Authors: Hui Zeng, Chen Xu, Junli Fan, Yueting Tang, Qiaoling Deng, Wei Zhang, Xinghua Long
Journal: JAMA (2020)

Lan Dong, MD; Jinhua Tian, MD; Songming He, MD; Chuchao Zhu, MD; Jian Wang, MD; Chen Liu, MD; Jing Yang, MD
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
Authors: Graziano Onder, Giovanni Rezza, Silvio Brusaferro
Journal: JAMA (2020)

This Viewpoint from physicians with the Italian National Institute of Health confirms a higher case-fatality rate from coronavirus disease 2019 (COVID-19) in Italy compared with China and explains possible reasons, including age, cause of death definitions, and testing strategy.
Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis
Authors: Jasmohan S. Bajaj, Andres Duarte-Rojo, Jesse J. Xie, Chathur Acharya, James B. Wade, Carlos Robles, Leroy R. Thacker, Christopher Flud, Andrew Fagan, Mauricio Garcia-Saenz-de-Sicilia, Melanie B. White, Megan Kelly, Vy Nguyen, Edith A. Gavis, Hugo E. Vargas
Journal: Clinical Gastroenterology and Hepatology (2020)
ACUTE GAIN IN MINIMAL LUMEN AREA FOLLOWING IMPLANTATION OF EVEROLIMUS-ELUTING ABSORB BIODEGRADABLE VASCULAR SCAFFOLDS OR XIENCE METALLIC STENTS: INTRAVASCULAR ULTRASOUND ASSESSMENT FROM THE ABSORB II TRIAL
Authors: Angel Cequier, Yuki Ishibashi, Hector Garcia Garcia, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2015)
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
Authors: Markus S. Anker, Maria K. Frey, Georg Goliasch, Philipp E. Bartko, Suriya Prausmüller, Heinz Gisslinger, Gabriela Kornek, Guido Strunk, Markus Raderer, Christoph Zielinski, Martin Hülsmann, Noemi Pavo
Journal: European Journal of Heart Failure (2020)
90. Identification of an Adeno-Associated Virus Binding Epitope for AVB Sepharose Affinity Resin
Authors: Qiang Wang, Martin Lock, Andrew Prongay, Mauricio R. Alvira, Boris Petkov, James M. Wilson
Journal: Molecular Therapy (2015)

Antibody-based affinity chromatography is increasingly becoming an important technology in clinical AAV vector production due to the one-step removal of the large majority of host cell contaminants and simplification of downstream processes. The affinity resin AVB Sepharose (GE) is widely used in AAV purification but has a major drawback in that it does not bind all serotypes of AAV equally well. Here we report the identification of an epitope, SPAKFA, of adeno-associated virus 3B (AAV3B) which specifically mediates binding to AVB Sepharose resin. Substitution of AAV3B SPAKFA for the corresponding peptide in two poorly-binding AAV serotypes, AAV8 and rh.64R1, resulted in greatly increased affinity to AVB sepharose. In addition, the capacity of AVB Sepharose for the AAV9 serotype, which binds extremely poorly in the context of the naturally occurring epitope, could be augmented substantially upon replacement with SPAKFA. Importantly, the substitution of the AAV3B SPAKFA peptide did not affect the potency of the serotypes tested in an in vitro assay. The sequence analysis -resin binding combination approach used here to identify the SPAKFA peptide may prove to be a powerful resin selection tool for novel AAV serotypes. In addition, our discovery suggests the possibility of vector engineering to yield a universal method for the purification of multiple AAV serotypes.
Abstract 14628: Characteristics and In-hospital Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
Authors: Elias B Hanna, Matthew T Roe, Stephen D Wiviott, Caroline S Fox, Anita Y Chen, Jorge F Saucedo
Journal: Circulation (2010)

Objective: Despite the high prevalence of chronic kidney disease (CKD), randomized trials that addressed the benefit of an invasive strategy in acute coronary syndromes excluded patients with advan...
Covid-19: Highest risk patients are asked to stay at home for 12 weeks
Authors: Zosia Kmietowicz
Journal: BMJ (2020)

A million and a half people in England who are at very high risk of severe illness and admission to hospital because of covid-12 will receive a letter this week asking them to stay at home for at least 12 weeks. Other people in the household will not have to remain inside but should adhere to Public Health England's advice to leave a distance of at least 2 m when interacting with other people. People falling into this extremely vulnerable group include those who have undergone an organ transplantation, those having certain treatments for cancer, those with certain respiratory conditions, and pregnant women with significant heart disease (box 1).1 They have been identified through general practice records, clinical reference groups, hospital trusts, and medical royal colleges. Box 1 ### Who should stay at home Among the groups of vulnerable people the government is saying should stay at home for 12 weeks are:RETURN TO TEXT
Abstract 15889: A Deep Learning Model to Predict Outcome After Thoracoscopic Surgery for Atrial Fibrillation Using Single Beat Electrocardiographic Samples
Authors: Sarah W Baalman, Lucas A Ramos, Ricardo R Lopes, Willeke Van Der Stuijt, Hidde Bleijendaal, Tom F Brouwer, Henk A Marquering, Antoine H Driessen, Reinoud E Knops, Joris R de Groot
Journal: Circulation (2019)

Introduction: Thoracoscopic surgery for atrial fibrillation (AF) has shown to be an effective treatment to restore sinus rhythm (SR) in AF patients with advanced AF. Identifying patients who may no...
A Family Affair
Authors: Alan D. Haber
Journal: Annals of Internal Medicine (2007)

On Being a Doctor15 May 2007A Family AffairAlan D. Haber, MDAlan D. Haber, MDFrom Graduate Hospital, Philadelphia, PA 19066.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-10-200705150-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail “Dad, where were you this morning?” my daughter inquired as I returned home late one night. My absence had been noteworthy. She and I share several physical and behavioral traits courtesy of our common genetics, one of them being the tendency to rise early. We are the larks of our family, and as her owl siblings sleep, we typically bond in the early morning hours—but not on this morning. Instead, I had been awakened at 5 a.m. by our intensive care unit fellow to review an admission. A 48-year-old patient with multiple myeloma, who had had an allogeneic bone marrow ... Author, Article, and Disclosure InformationAffiliations: From Graduate Hospital, Philadelphia, PA 19066.Corresponding Author: Alan D. Haber, MD, 335 Sycamore Avenue, Merion Station, PA 19066; e-mail, alan.[email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 May 2007Volume 146, Issue 10Page: 753-754KeywordsBlood pressureBody weightBone marrowChildrenIntensive care unitsOxygenSepsisTouchVasopressorsVentilators ePublished: 15 May 2007 Issue Published: 15 May 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma
Authors: Kunpeng Bu, Yang Lu, Xiaoyan Liu, Chunyan Cheng, Bixun Li
Journal: Journal of Thoracic Oncology (2020)
Dominant-negative mutations in human <i>IL6ST</i> underlie hyper-IgE syndrome
Authors: Vivien Béziat, Simon J. Tavernier, Yin-Huai Chen, Cindy S. Ma, Marie Materna, Arian Laurence, Jens Staal, Dominik Aschenbrenner, Lisa Roels, Lisa Worley, Kathleen Claes, Lisa Gartner, Lisa A. Kohn, Marieke De Bruyne, Klaus Schmitz-Abe, Louis-Marie Charbonnier, Sevgi Keles, Justine Nammour, Natasha Vladikine, Majistor Raj Luxman Maglorius Renkilaraj, Yoann Seeleuthner, Mélanie Migaud, Jérémie Rosain, Mohamed Jeljeli, Bertrand Boisson, Eva Van Braeckel, Jill A. Rosenfeld, Hongzheng Dai, Lindsay C. Burrage, David R. Murdock, Bart N. Lambrecht, Véronique Avettand-Fenoel, Tiphanie P. Vogel, Charles R. Esther, Sule Haskologlu, Figen Dogu, Peter Ciznar, David Boutboul, Marie Ouachée-Chardin, Jean Amourette, Marie-Noëlle Lebras, Clément Gauvain, Colas Tcherakian, Aydan Ikinciogullari, Rudi Beyaert, Laurent Abel, Joshua D. Milner, Bodo Grimbacher, Louis-Jean Couderc, Manish J. Butte, Alexandra F. Freeman, Émilie Catherinot, Claire Fieschi, Talal A. Chatila, Stuart G. Tangye, Holm H. Uhlig, Filomeen Haerynck, Jean-Laurent Casanova, Anne Puel
Journal: The Journal of Experimental Medicine (2020)

Autosomal dominant hyper-IgE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations. Patients suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal abnormalities. We report 12 patients from 8 unrelated kindreds with AD-HIES due to DN IL6ST mutations. We identified seven different truncating mutations, one of which was recurrent. The mutant alleles encode GP130 receptors bearing the transmembrane domain but lacking both the recycling motif and all four STAT3-recruiting tyrosine residues. Upon overexpression, the mutant proteins accumulate at the cell surface and are loss of function and DN for cellular responses to IL-6, IL-11, LIF, and OSM. Moreover, the patients' heterozygous leukocytes and fibroblasts respond poorly to IL-6 and IL-11. Consistently, patients with STAT3 and IL6ST mutations display infectious and allergic manifestations of IL-6R deficiency, and some of the skeletal abnormalities of IL-11R deficiency. DN STAT3 and IL6ST mutations thus appear to underlie clinical phenocopies through impairment of the IL-6 and IL-11 response pathways.
Rising to the Challenge of COVID-19: Advice for Pulmonary and Critical Care and an Agenda for Research
Authors: Michael S. Niederman, Luca Richeldi, Sanjay H. Chotirmall, Chunxue Bai
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

The explosion of coronavirus disease , the illness related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had worldwide health implications, but it is a particular challenge to those of us who practice Pulmonary and Critical Care Medicine (PCCM) because of the high rate of respiratory tract involvement, the frequent presence of pneumonia in these patients, and the high mortality rate for those with respiratory failure, particularly in the ICU (1, 2).In China, although 80% had mild illness, approximately one quarter of those who were hospitalized for COVID-19 needed ICU care.For those in the ICU, mortality was 49%, whereas those with Acute Respiratory Distress Syndrome (ARDS) had a mortality of 52.4% (1, 3).As has become clear, many countries have not been able to contain COVID-19 spread because of unavailability of early widespread testing, undertesting of those at risk, failing to trace all contacts of infected patients, and in some overcrowded settings, nosocomial spread of the infection.There is concern about a shortage of ICU beds and ventilators, trained medical staff, adequate personal protective equipment (PPE), and everchanging recommendations about management and supportive care, at a time when no definitive therapy for COVID-19 is available.All of these factors put great strain on PCCM clinicians, and we need to have a plan for meeting these challenges.In this editorial, we provide suggestions based on our experiences with this epidemic to guide our colleagues.We adhere to Benjamin Franklin's assessment that "by failing to prepare, you are preparing to fail."Some important basic facts about COVID-19 are still being determined, most importantly the mortality rate.While some series report mortality rates as high as 3-4%, the rates vary widely by age, comorbidity, and severity of illness on presentation (4).Predictors of mortality have included older age, elevated D-dimer on admission, and higher degree of initial organ dysfunction (4).However, the calculated mortality rate is also a reflection of the degree of widespread diagnostic testing, because many infected individuals have minimal symptoms and may not be routinely evaluated.In South Korea, efforts have been made to test the broad population, and when a more accurate number of infected individuals is included, the overall mortality rate may be ,1%.However, this makes COVID-19 more deadly than seasonal influenza, which has a 0.1% mortality rate; this may reflect not only
TCT-552 Particulates from Hydrophilic Coated Guiding Sheaths Embolize to the Brain
Authors: James Stanley, Kathryn Regan, Alan LaRochelle, Brett Zani, Peter Markham, Lynn Bailey, Anna-Maria Spognardi, Gee Wong, Abraham R Tzafriri, Gregory A. Kopia, Elazer Edelman
Journal: Journal of the American College of Cardiology (2014)
Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1
Authors: Tim Wilhelmi, Xingbo Xu, Xiaoying Tan, Melanie S. Hulshoff, Sabine Maamari, Samuel Sossalla, Michael Zeisberg, Elisabeth M. Zeisberg
Journal: Theranostics (2020)

Rationale: Cardiac fibrosis is an integral constituent of every form of chronic heart disease, and persistence of fibrosis reduces tissue compliance and accelerates the progression to heart failure. Relaxin-2 is a human hormone, which has various physiological functions such as mediating renal vasodilation in pregnancy. Its recombinant form Serelaxin has recently been tested in clinical trials as a therapy for acute heart failure but did not meet its primary endpoints. The aim of this study is to examine whether Serelaxin has an anti-fibrotic effect in the heart and therefore could be beneficial in chronic heart failure. Methods: We utilized two different cardiac fibrosis mouse models (ascending aortic constriction (AAC) and Angiotensin II (ATII) administration via osmotic minipumps) to assess the anti-fibrotic potential of Serelaxin. Histological analysis, immunofluorescence staining and molecular analysis were performed to assess the fibrosis level and indicate endothelial cells which are undergoing EndMT. In vitro TGFβ1-induced endothelial-to-mesenchymal transition (EndMT) assays were performed in human coronary artery endothelial cells and mouse cardiac endothelial cells (MCECs) and were examined using molecular methods. Chromatin immunoprecipitation-qPCR assay was utilized to identify the Serelaxin effect on chromatin remodeling in the Rxfp1 promoter region in MCECs. Results: Our results demonstrate a significant and dose-dependent anti-fibrotic effect of Serelaxin in the heart in both models. We further show that Serelaxin mediates this effect, at least in part, through inhibition of EndMT through the endothelial Relaxin family peptide receptor 1 (RXFP1). We further demonstrate that Serelaxin administration is able to increase its own receptor expression (RXFP1) through epigenetic regulation in form of histone modifications by attenuating TGFβ-pSMAD2/3 signaling in endothelial cells. Conclusions: This study is the first to identify that Serelaxin increases the expression of its own receptor RXFP1 and that this mediates the inhibition of EndMT and cardiac fibrosis, suggesting that Serelaxin may have a beneficial effect as anti-fibrotic therapy in chronic heart failure.
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Authors: Kristen Fousek, Junji Watanabe, Sujith K. Joseph, Ann George, Xingyue An, Tiara T. Byrd, Jessica S. Morris, Annie Luong, Melisa A. Martínez-Paniagua, Khaled Sanber, Shoba A. Navai, Ahmed Z. Gad, Vita S. Salsman, Pretty R. Mathew, Hye Na Kim, Dimitrios L. Wagner, Lorenzo Brunetti, Albert Jang, Matthew L. Baker, Navin Varadarajan, Meenakshi Hegde, Yong-Mi Kim, Nora Heisterkamp, Hisham Abdel-Azim, Nabil Ahmed
Journal: Leukemia (2020)

Abstract Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(−) disease. We report that CD19(−) escape is associated with downregulation, but preservation, of targetable expression of CD20 and CD22. Accordingly, we reasoned that broadening the spectrum of CD19CAR T-cells to include both CD20 and CD22 would enable them to target CD19(−) escape BL-ALL while preserving their upfront efficacy. We created a CD19/20/22-targeting CAR T-cell by coexpressing individual CAR molecules on a single T-cell using one tricistronic transgene. CD19/20/22CAR T-cells killed CD19(−) blasts from patients who relapsed after CD19CAR T-cell therapy and CRISPR/Cas9 CD19 knockout primary BL-ALL both in vitro and in an animal model, while CD19CAR T-cells were ineffective. At the subcellular level, CD19/20/22CAR T-cells formed dense immune synapses with target cells that mediated effective cytolytic complex formation, were efficient serial killers in single-cell tracking studies, and were as efficacious as CD19CAR T-cells against primary CD19(+) disease. In conclusion, independent of CD19 expression, CD19/20/22CAR T-cells could be used as salvage or front-line CAR therapy for patients with recalcitrant disease.
BALLOON AORTIC VALVULOPLASTY AS A BRIDGE TO AORTIC VALVE REPLACEMENT A CONTEMPORARY NATIONAL PERSPECTIVE
Authors: Mohammad Akram Kawsara, Fahad Alqahtani, Mohamed Alhajji, Sirish Shrestha, Khaled Ziada, Mohamad Adnan Alkhouli
Journal: Journal of the American College of Cardiology (2020)
TCT-71 Influence of Local Myocardial Damage on Index of Microcirculatory Resistance and Fractional Flow Reserve in Target and Non-target Vascular Territories in a Porcine Microvascular Injury Model
Authors: Joo Myung Lee, Hyun Kuk Kim, Kyung Seob Lim, Ki Hong Choi, Jonghanne Park, Doyeon Hwang, Tae-Min Rhee, Jeong Hoon Yang, Eun-Seok Shin, Chang-Wook Nam, Joon-Hyung Doh, Joo-Yong Hahn, Bon-Kwon Koo, Myung Ho Jeong
Journal: Journal of the American College of Cardiology (2017)
Leading HIV Vaccine Trial Stopped for Ineffectiveness
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-333 Prognostic Implication of Functional Incomplete Revascularization and Residual Functional SYNTAX Score in Patients with Coronary Artery Disease
Authors: Ki Hong Choi, Joo Myung Lee, Bon-Kwon Koo, Chang-Wook Nam, Eun-Seok Shin, Joon-Hyung Doh, Doyeon Hwang, Jonghanne Park
Journal: Journal of the American College of Cardiology (2017)
TCTAP A-119 Incidence and Procedural Outcome of Bicuspid Aortic Valve in 684 Patients Undergoing Transcatheter Aortic Valve Implantation
Authors: Won-Keun Kim, Andreas Rolf, Susanne Moellmann, Johannes Blumenstein, Christoph Liebetrau, Christian Hamm, Thomas Walther, Helge Moellmann
Journal: Journal of the American College of Cardiology (2015)